Allos Therapeutics Files Shelf Registration Statement
13 June 2006 - 10:12PM
PR Newswire (US)
WESTMINSTER, Colo., June 13 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) announced today that it has filed
a universal shelf registration statement with the Securities and
Exchange Commission (SEC) that, if declared effective by the SEC,
will allow the Company to sell, from time to time, up to $100
million of its common stock, preferred stock, depository shares,
debt securities and/or warrants, either individually or in units,
in one or more offerings. As of the date of this release, the
Company has no specific plans to offer the securities covered by
the registration statement and the Company is not required to offer
the securities in the future pursuant to the registration
statement. The terms of any offering under the registration
statement will be established at the time of the offering. Proceeds
from the sale of any securities will be used for the purposes
described in a prospectus supplement filed at the time of an
offering. If and when the SEC declares this registration statement
effective, the Company intends to retire the unused portion of its
previous shelf registration statement that was declared effective
by the SEC in 2004. The Company expects to use the net proceeds
from any sale of securities under this registration statement to
fund the costs of its clinical trials and other research and
development activities, both on-going and planned, to support the
potential commercialization of EFAPROXYN in the event that the
Company obtains regulatory approval to market EFAPROXYN, and for
general corporate purposes, including working capital. A shelf
registration statement relating to these securities was filed today
with the SEC but has not yet become effective. The securities
offered by the Company pursuant to the registration statement may
not be sold, nor may offers to buy the securities be accepted prior
to the time the registration statement becomes effective. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of the
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (NASDAQ:ALTH) is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule therapeutics for the treatment of cancer.
The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral),
is a synthetic small molecule designed to sensitize hypoxic, or
oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN
is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. The Company's other product
candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under
investigation in patients with non-small cell lung cancer and
Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic
agent bioactivated by the enzyme DT-diaphorase currently under
evaluation in patients with advanced solid tumors. For more
information, please visit the Company's web site at:
http://www.allos.com/. Safe Harbor Statement This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. You can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends,"
"plans," anticipates," "believes," "estimates," "predicts,"
"projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean
that a particular statement is not forward- looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others, those described in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2005 and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227, Web
site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024